PURPOSE: The intercellular adhesion molecule (ICAM)-1 is expressed on many cell types including endothelial cells and different cancer cell entities. Experimental data strongly indicate that ICAM-1 can activate intracellular signalling pathways in cancer cells leading to enhanced cell motility, invasion and metastasis. Yet, little is known about the role of ICAM-1 expression during malignant progression in breast cancer patients. METHODS: We investigated ICAM-1 protein and mRNA expression in two partly overlapping cohorts of breast cancer patients. ICAM-1 protein was detected by Western blot analysis in 104 cases and verified by immunohistochemistry. Additionally, ICAM-1 mRNA microarray data from 169 tumours were analysed. RESULTS: With both methods, high ICAM-1 expression was significantly associated with a poorly differentiated phenotype, a negative estrogen receptor (ER) status and positive lymph node involvement. In addition, there was a significant prognostic impact of ICAM-1 protein overexpression on recurrence-free survival (HR = 2.82, P = 0.023), which was most pronounced in ER-negative tumours. ICAM-1 mRNA overexpression was associated with high urokinase plasminogen activator (uPA) and uPA-inhibitor protein 1 (PAI 1) protein and mRNA levels as well as high Ki67 protein and vascular endothelial growth factor (VEGF) mRNA expression. CONCLUSIONS: In our group of patients, ICAM-1 expression was associated with a more aggressive tumour phenotype. Because of its association with malignant progression, ICAM-1 might represent a new target in the treatment of breast cancer patients.
PURPOSE: The intercellular adhesion molecule (ICAM)-1 is expressed on many cell types including endothelial cells and different cancer cell entities. Experimental data strongly indicate that ICAM-1 can activate intracellular signalling pathways in cancer cells leading to enhanced cell motility, invasion and metastasis. Yet, little is known about the role of ICAM-1 expression during malignant progression in breast cancerpatients. METHODS: We investigated ICAM-1 protein and mRNA expression in two partly overlapping cohorts of breast cancerpatients. ICAM-1 protein was detected by Western blot analysis in 104 cases and verified by immunohistochemistry. Additionally, ICAM-1 mRNA microarray data from 169 tumours were analysed. RESULTS: With both methods, high ICAM-1 expression was significantly associated with a poorly differentiated phenotype, a negative estrogen receptor (ER) status and positive lymph node involvement. In addition, there was a significant prognostic impact of ICAM-1 protein overexpression on recurrence-free survival (HR = 2.82, P = 0.023), which was most pronounced in ER-negative tumours. ICAM-1 mRNA overexpression was associated with high urokinase plasminogen activator (uPA) and uPA-inhibitor protein 1 (PAI 1) protein and mRNA levels as well as high Ki67 protein and vascular endothelial growth factor (VEGF) mRNA expression. CONCLUSIONS: In our group of patients, ICAM-1 expression was associated with a more aggressive tumour phenotype. Because of its association with malignant progression, ICAM-1 might represent a new target in the treatment of breast cancerpatients.
Authors: Jennifer J Rahn; Jeffrey W Chow; Garnet J Horne; Brian K Mah; Joanne T Emerman; Pat Hoffman; Judith C Hugh Journal: Clin Exp Metastasis Date: 2005 Impact factor: 5.150
Authors: Caridad Rosette; Richard B Roth; Paul Oeth; Andreas Braun; Stefan Kammerer; Jonas Ekblom; Mikhail F Denissenko Journal: Carcinogenesis Date: 2005-03-17 Impact factor: 4.944
Authors: Isabell D Witzel; Karin Milde-Langosch; Ralph M Wirtz; Claudia Roth; Maike Ihnen; Sven Mahner; Christine Zu Eulenburg; Fritz Jänicke; Volkmar Müller Journal: J Cancer Res Clin Oncol Date: 2010-03-04 Impact factor: 4.553
Authors: S K Ranamukhaarachchi; R N Modi; A Han; D O Velez; A Kumar; A J Engler; S I Fraley Journal: Biomater Sci Date: 2019-01-29 Impact factor: 6.843
Authors: Ye Wang; Liuqun Jia; Yongchun Shen; Shujin Guo; Chun Wan; Ting Yang; Jing An; Lei Chen; Tao Wang; Fuqiang Wen Journal: Int J Clin Exp Med Date: 2014-01-15
Authors: Zhiwei Hu; Samira A Brooks; Valérian Dormoy; Chia-Wen Hsu; Hsue-Yin Hsu; Liang-Tzung Lin; Thierry Massfelder; W Kimryn Rathmell; Menghang Xia; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Dustin G Brown; Kalan R Prudhomme; Annamaria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Leroy Lowe; Lasse Jensen; William H Bisson; Nicole Kleinstreuer Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944
Authors: Tobias Piegeler; E Gina Votta-Velis; Guoquan Liu; Aaron T Place; David E Schwartz; Beatrice Beck-Schimmer; Richard D Minshall; Alain Borgeat Journal: Anesthesiology Date: 2012-09 Impact factor: 7.892
Authors: Dina Schütze; Karin Milde-Langosch; Isabell Witzel; Achim Rody; Thomas Karn; Marcus Schmidt; Matthias Choschzick; Fritz Jänicke; Volkmar Müller Journal: J Cancer Res Clin Oncol Date: 2013-01-29 Impact factor: 4.553